TRILACICLIB

Search structure


Synonyms:	G1T28 Trilaciclib
Status:	Phase 2
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
UNII:	U6072DO9XG

Structure


InChI Key	PDGKHKMBHVFCMG-UHFFFAOYSA-N
Smile	CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1
InChI	InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H30N8O
Molecular Weight	446.56
AlogP	2.72
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	91.21
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	33.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Cyclin-dependent kinase 4 inhibitor	PubMed PubMed FDA

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Kinase Protein Kinase CMGC protein kinase group	-	1	-	-	-
Other cytosolic protein	-	1	-	-	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Small Cell Lung Carcinoma	3	D055752	ClinicalTrials
Triple Negative Breast Neoplasms	3	D064726	ClinicalTrials
Hemangiosarcoma	2	D006394	ClinicalTrials
Breast Neoplasms	2	D001943	ClinicalTrials
Carcinoma, Non-Small-Cell Lung	2	D002289	ClinicalTrials

Cross References

Resources	Reference
CAS NUMBER	1374743-00-6
ChEMBL	CHEMBL3894860
DrugBank	DB15442
FDA SRS	U6072DO9XG
Guide to Pharmacology	9626
PubChem	68029831
SureChEMBL	SCHEMBL10082028

CONTENTS